Myriad Genetics, Inc. (MYGN)

NASDAQ: MYGN · IEX Real-Time Price · USD
21.54
-1.96 (-8.34%)
Feb 28, 2024, 1:35 PM EST - Market open
-8.34%
Market Cap 2.03B
Revenue (ttm) 734.40M
Net Income (ttm) -274.40M
Shares Out 89.64M
EPS (ttm) -3.36
PE Ratio n/a
Forward PE 40.98
Dividend n/a
Ex-Dividend Date n/a
Volume 588,665
Open 23.25
Previous Close 23.50
Day's Range 21.34 - 23.75
52-Week Range 13.82 - 24.21
Beta 2.00
Analysts Buy
Price Target 23.14 (+7.43%)
Earnings Date Feb 27, 2024

About MYGN

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metast... [Read more]

Sector Healthcare
IPO Date Oct 5, 1995
Employees 2,600
Stock Exchange NASDAQ
Ticker Symbol MYGN
Full Company Profile

Financial Performance

In 2022, MYGN's revenue was $678.40 million, a decrease of -1.77% compared to the previous year's $690.60 million. Losses were -$112.00 million, 311.8% more than in 2021.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for MYGN stock is "Buy." The 12-month stock price forecast is $23.14, which is an increase of 7.43% from the latest price.

Price Target
$23.14
(7.43% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the Fourth Quarter 2023; Raising 2024 Revenue Guidance

Highlights: Full-year testing volume grew 35% year-over-year, or 18% ex-SneakPeek ® volume. Full-year 2023 revenue of $753 million , grew 11% year-over-year driven by Prenatal (30%, 15% ex-SneakPeek),...

21 hours ago - GlobeNewsWire

Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3

Myriad's Precise MRD test will be used to evaluate the broad applicability of MRD testing across many cancer types Myriad's Precise MRD test will be used to evaluate the broad applicability of MRD tes...

1 day ago - GlobeNewsWire

Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024

Management will also participate in two upcoming healthcare conferences Management will also participate in two upcoming healthcare conferences

6 days ago - GlobeNewsWire

Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women's Health

SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Dallas Reed, MD, FACOG,...

12 days ago - GlobeNewsWire

Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics

SALT LAKE CITY, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has completed the acquisition from Inte...

27 days ago - GlobeNewsWire

Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology

SALT LAKE CITY, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of George Daneker Jr., MD,...

4 weeks ago - GlobeNewsWire

Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics

SALT LAKE CITY, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has entered into a definitive agreement...

5 weeks ago - GlobeNewsWire

Myriad Genetics Applauds New Germline Testing Guideline for Patients with Breast Cancer from ASCO-SSO

SALT LAKE CITY, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced its support for the American Society of Cl...

7 weeks ago - GlobeNewsWire

Myriad Genetics to Present at 42nd Annual J.P. Morgan Healthcare Conference

SALT LAKE CITY, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Myriad management will present at the 42nd...

7 weeks ago - GlobeNewsWire

Myriad Genetics Chief Financial Officer Bryan Riggsbee Retires; Scott Leffler Appointed as Successor; Reiterates Previously Issued Financial Guidance

SALT LAKE CITY, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Scott Leffler as Chief F...

2 months ago - GlobeNewsWire

Myriad Genetics Establishes Comprehensive Pan-Cancer Research Platform to Advance Patient Care

The Myriad Collaborative Research Registry has more than one million patient cases The Myriad Collaborative Research Registry has more than one million patient cases

2 months ago - GlobeNewsWire

Kiyatec strengthens its leadership position with the addition of Mark Capone, former CEO of Myriad Genetics, as Strategic Advisor

GREENVILLE, S.C.--(BUSINESS WIRE)--Kiyatec, a leading functional precision oncology company specializing in 3D cell culture technology and delivering evidence of therapeutic response in the oncology s...

3 months ago - Business Wire

Myriad Genetics Celebrates One Million SneakPeek® Results Shared with Expectant Parents

SALT LAKE CITY, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has delivered results to one million con...

3 months ago - GlobeNewsWire

Myriad Genetics and Personalis Partner to Market Solutions to Pharma Customers

Myriad expands pharma service offering by introducing Personalis' ImmunoID NeXT® platform to its pharmaceutical partners who use MyRisk® Hereditary Cancer Test, BRACAnalysis CDx® and/or MyChoice® CDx ...

3 months ago - GlobeNewsWire

Myriad Genetics to Participate in Stephens Annual Investment Conference

SALT LAKE CITY, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Myriad management will participate in the S...

3 months ago - GlobeNewsWire

Myriad Genetics Announces Pricing of Upsized Offering of Common Stock

SALT LAKE CITY, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN) (the “Company” or “Myriad Genetics”), a leader in genetic testing and precision medicine, today announced the pri...

3 months ago - GlobeNewsWire

Myriad Genetics Announces Proposed Offering of $100 Million of Shares of Common Stock

SALT LAKE CITY, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN) (the “Company” or “Myriad Genetics”), a leader in genetic testing and precision medicine, today announced that it...

3 months ago - GlobeNewsWire

Myriad Genetics Reports Third Quarter 2023 Financial Results; Generates Double-Digit Revenue Growth; Raises 2023 Revenue Guidance and Introduces 2024 Revenue Guidance

Highlights: Third quarter testing volume grew 18% year-over-year, excluding contributions from the SneakPeek ® Early Gender DNA Test, the fifth consecutive quarter of double-digit year-over-year growt...

4 months ago - GlobeNewsWire

Myriad Genetics Appoints Sam Raha as Chief Operating Officer

SALT LAKE CITY, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Sam Raha as Chief Operat...

4 months ago - GlobeNewsWire

Myriad Genetics to Release Third Quarter Financial Results on November 6, 2023

SALT LAKE CITY, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its third quarter earnings conference call on Mon...

4 months ago - GlobeNewsWire

BREAST CANCER AWARENESS MONTH: NEW CANCER RISK SURVEY REVEALS RISK FACTORS ARE WIDELY MISUNDERSTOOD

SALT LAKE CITY , Sept. 28, 2023 /PRNewswire/ -- A new national survey from Myriad Genetics Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, revealed that breast density and fam...

5 months ago - PRNewsWire

New Myriad Genetics Survey Shows Breast Cancer Risk Factors Are Misunderstood

SALT LAKE CITY, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics , Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced results from a nationwide survey revealing...

5 months ago - GlobeNewsWire

Myriad Genetics and Illumina Achieve Milestones in Strategic Partnership to Support Biopharma Clinical Trials

Myriad can conduct prospective clinical trials using Illumina's TruSight Oncology Comprehensive Investigational Use Only test Myriad can conduct prospective clinical trials using Illumina's TruSight O...

5 months ago - GlobeNewsWire

Myriad Genetics Issues 2022 Environmental, Social and Governance Report

SALT LAKE CITY, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today released its second annual Environmental, Social and...

5 months ago - GlobeNewsWire

Myriad Genetics and Leading Cancer Center Collaborate to Study the Use of Minimal Residual Disease Testing in Breast Cancer

Research will use Myriad's high-definition MRD testing platform based on whole-genome sequencing Research will use Myriad's high-definition MRD testing platform based on whole-genome sequencing

5 months ago - GlobeNewsWire